HealthDay News—The proportion of human papillomavirus (HPV) 16/18-positive cervical intraepithelial neoplasia grades 2 to 3 or adenocarcinoma in situ (CIN2+) declined from 2008 to 2014, according to a study published online Feb. 21 in Cancer Epidemiology, Biomarkers & Prevention.
Nancy M. McClung, PhD, from the US Centers for Disease Control and Prevention in Atlanta, and colleagues analyzed data from a 5-site surveillance system. The authors tested archived specimens from women aged 18 to 39 years diagnosed with CIN2+ for 37 HPV types.
The researchers found that the proportion and estimated number of cases of HPV 16/18-positive CIN2+ among 10,206 cases declined from 52.7% to 44.1% from 2008 to 2014 (1235 to 819 cases). The proportion of HPV 16/18-positive CIN2+ declined among vaccinated (55.2% to 33.3%) and unvaccinated (51% to 47.3%) women; those aged 18 to 20 (48.7% to 18.8%), 21 to 24 (53.8% to 44%), 25 to 29 (56.9% to 42.4%), and 30 to 34 years (49.8% to 45.8%); CIN2/3 (61.8% to 46.2%); and non-Hispanic whites (59.5% to 47.9%) and non-Hispanic blacks (40.7% to 26.5%).
“This is clear evidence that the HPV vaccine is working to prevent cervical disease in young women in the United States,” McClung said in a statement. “In the coming years, we should see even greater impact as more women are vaccinated during early adolescence and before exposure to HPV.”
One author disclosed financial ties to Merck.